Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 5, 2009, Pages 723-730

  Zimmer, Sebastian ^a   Kahl, Philip ^a   Buhl, Theresa M ^a   Steiner, Susanne ^a   Wardelmann, Eva ^a   Merkelbach Bruse, Sabine ^a   Buettner, Reinhard ^a   Heukamp, Lukas C ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Akt; EGFR; MAPK; NSCLC; Stat3

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN;

ADULT; AGED; ARTICLE; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA, NEOPLASM; EXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 63549094156     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0509-9     Document Type: Article

References (32)

1. JV Alvarez H Greulich WR Sellers M Meyerson DA Frank 2006 Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor Cancer Res 66 3162 3168 10.1158/0008-5472.CAN-05-3757
2. D Atkins KA Reiffen CL Tegtmeier H Winther MS Bonato S Storkel 2004 Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections J Histochem Cytochem 52 893 901 10.1369/jhc.3A6195.2004
3. AG Batzer D Rotin JM Urena EY Skolnik J Schlessinger 1994 Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor Mol Cell Biol 14 5192 5201
4. KS Bishnupuri Q Luo N Murmu CW Houchen S Anant BK Dieckgraefe 2006 Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas Gastroenterology 130 137 149 10.1053/j.gastro.2005.10.001
5. E Brambilla WD Travis TV Colby B Corrin Y Shimosato 2001 The new World Health Organization classification of lung tumours Eur Respir J 18 1059 1068 10.1183/09031936.01.00275301
6. J Brognard AS Clark Y Ni PA Dennis 2001 Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation Cancer Res 61 3986 3997
7. Z Cao L Liu DM Van Winkle 2005 Met5-enkephalin-induced cardioprotection occurs via transactivation of EGFR and activation of PI3K Am J Physiol Heart Circ Physiol 288 H1955 H1964 10.1152/ajpheart.00256.2004
8. F Cappuzzo E Magrini GL Ceresoli S Bartolini E Rossi V Ludovini V Gregorc C Ligorio A Cancellieri S Damiani A Spreafico CT Paties 2004 Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 1133 1141
9. A Chattopadhyay M Vecchi Q Ji R Mernaugh G Carpenter 1999 The role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptor J Biol Chem 274 26091 26097 10.1074/jbc.274.37.26091
10. JQ Cheng B Ruggeri WM Klein G Sonoda DA Altomare DK Watson JR Testa 2001 Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA Proc Natl Acad Sci USA 93 3636 3641 10.1073/pnas.93.8.3636
11. F Ciardiello G Tortora 2001 A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin Cancer Res 7 2958 2970
12. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa JY Douillard Y Nishiwaki J Vansteenkiste S Kudoh D Rischin R Eek T Horai 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2237 2246 10.1200/JCO.2003.10.038
13. EB Haura Z Zheng L Song A Cantor G Bepler 2005 Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer Clin Cancer Res 11 8288 8294 10.1158/1078-0432.CCR-05-0827
14. LC Heukamp HP Fischer P Schirmacher X Chen K Breuhahn C Nicolay R Buttner I Gutgemann 2006 Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions Histopathology 49 242 247 10.1111/j.1365-2559. 2006.02489.x
15. FR Hirsch M Varella-Garcia PA Bunn Jr MV Di Maria R Veve RM Bremmes AE Baron C Zeng WA Franklin 2003 Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 3798 3807 10.1200/JCO.2003.11.069
16. FR Hirsch M Varella-Garcia PA Bunn Jr WA Franklin R Dziadziuszko N Thatcher A Chang P Parikh JR Pereira T Ciuleanu J von Pawel C Watkins 2006 Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 5034 5042 10.1200/JCO.2006.06.3958
17. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66
18. GL Johnson RR Vaillancourt 1994 Sequential protein kinase reactions controlling cell growth and differentiation Curr Opin Cell Biol 6 230 238 10.1016/0955-0674(94)90141-4
19. RN Jorissen F Walker N Pouliot TP Garrett CW Ward AW Burgess 2003 Epidermal growth factor receptor: mechanisms of activation and signalling Exp Cell Res 284 31 53 10.1016/S0014-4827(02)00098-8
20. MG Kris RB Natale RS Herbst TJ Lynch Jr D Prager CP Belani JH Schiller K Kelly H Spiridonidis A Sandler KS Albain D Cella 2003 Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2149 2158 10.1001/jama.290.16.2149
21. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan PL Harris SM Haserlat JG Supko FG Haluska DN Louis DC Christiani 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 10.1056/NEJMoa040938
22. JG Paez PA Janne JC Lee S Tracy H Greulich S Gabriel P Herman FJ Kaye N Lindeman TJ Boggon K Naoki H Sasaki 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 10.1126/science.1099314
23. HS Parra R Cavina F Latteri PA Zucali E Campagnoli E Morenghi GC Grimaldi M Roncalli A Santoro 2004 Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer Br J Cancer 91 208 212
24. D Rotin B Margolis M Mohammadi RJ Daly G Daum N Li EH Fischer WH Burgess A Ullrich J Schlessinger 1992 SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma Embo J 11 559 567
25. G Selvaggi S Novello V Torri E Leonardo P De Giuli P Borasio C Mossetti F Ardissone P Lausi GV Scagliotti 2004 Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer Ann Oncol 15 28 32 10.1093/annonc/mdh011
26. RE Sobol RW Astarita C Hofeditz H Masui R Fairshter I Royston J Mendelsohn 1987 Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody J Natl Cancer Inst 79 403 407
27. R Sordella DW Bell DA Haber J Settleman 2004 Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 1163 1167 10.1126/science.1101637
28. CM Stoscheck LE King Jr 1986 Role of epidermal growth factor in carcinogenesis Cancer Res 46 1030 1037
29. LM Sturla G Amorino MS Alexander RB Mikkelsen K Valerie RK Schmidt-Ullrichr 2005 Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2 J Biol Chem 280 14597 14604 10.1074/jbc.M413287200
30. V Vasko M Saji E Hardy M Kruhlak A Larin V Savchenko M Miyakawa O Isozaki H Murakami T Tsushima KD Burman C De Micco 2004 Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer J Med Genet 41 161 170 10.1136/jmg.2003.015339
31. QC Vega C Cochet O Filhol CP Chang SG Rhee GN Gill 1992 A site of tyrosine phosphorylation in the C terminus of the epidermal growth factor receptor is required to activate phospholipase C Mol Cell Biol 12 128 135
32. ZQ Yuan M Sun RI Feldman G Wang X Ma C Jiang D Coppola SV Nicosia JQ Cheng 2000 Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer Oncogene 19 2324 2330 10.1038/sj.onc.1203598